

Technology Advisory Committee C Interests Register

Topic Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation [ID6198]

Publication Date: 05/06/2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Michael Chambers	TAC C Committee Member	Direct- financial	Michael is a member of an advisory panel for Pfizer (possible comparator company) in an unrelated disease area (prostate cancer).	17/01/2024	It was agreed that Michael's declaration would not prevent him from participating in discussions on this appraisal
Dr Kate Ren	TAC C Committee Member	Direct- financial	Dr Ren has provided statistical methodology consultancy service for a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area (Tofacitinib for Moderate-to-Severe Ulcerative Colitis)	17/01/2024	It was agreed that Dr Ren's declaration would not prevent her from participating in discussions on this appraisal
Satish Venkateshan	TAC C Committee Member	Direct- financial	Regeneron is developing therapeutics for a broad range of diseases including haematologic malignancies. Satish works for Regeneron, a pharmaceuticals/biotech company. Satish also owns shares in the company and has stock options.	22/01/2024	It was agreed that Satish's declaration would prevent him from participating in discussions on this appraisal

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Richard Ballerand	TAC C Committee Member (volunteer)	Direct non- financial	Richard Ballerand was a member of Servier's Patient Advisory Board providing patient input for the setting up of the Servier Paris-Saclay Research & Development Institute (2021-23) - no involvement with or awareness of any of their drugs.	28/03/2024	It was agreed that Richard Ballerand's declaration would not prevent him from participating in discussions on this appraisal.
Dr Richard Dillon	Clinical expert	Direct- financial Direct non- financial	Dr Dillon was on an advisory board regarding Ivosidenib on 28/04/2022. Dr Dillon received travel support for attending conferences.	08/09/2023	It was agreed that Dr Dillon's declaration would not prevent him from providing expert advice to the committee
Charlotte Crowley	Patient expert	Indirect-financial	Charlotte's nominating organisation has received: • Abbvie: £12,000 core funding and £450 honorarium • Jazz: £30,000 awareness and patient support • Pfizer: £10,000 core funding	17/11/2023	It was agreed that Charlotte's declaration would not prevent her from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Celgene: £65,000 patient activities of which £15,000 is for the Blood		